Feature | April 18, 2007 | Cristen C. Bolan

WEB EXCLUSIVE: Quantification Pushes Nuclear Medicine Bedside

2006 - 2007 SNM President Martin P. Sandler, M.D., Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences

“I think quantification is the next big breakthrough in imaging technology,” said the 2006 – 2007 SNM President Martin P. Sandler, M.D., of Vanderbilt University Medical Center, Department of Radiology and Radiological Sciences, in an interview with Imaging Technology News (ITN) on the future of nuclear medicine.
The Society of Nuclear Medicine (SNM) has embarked on a mission to improve healthcare by advancing molecular imaging and therapy, and the SNM 2007 conference program will feature an increased presence of related research. ITN talked to Dr. Sandler about how nuclear medicine will drive personalized medicine in the future.

ITN: How is molecular imaging using imaging technology such as PET, SPECT, MRI and others to develop personalized medicine?

Martin P. Sandler, M.D. (MS): It is the understanding of how cellular function and biological processes of the cell work from the receptor through the cell membrane all the way to the inner functions of the cell. By looking at different receptor sites and different activities of the cell one can develop specific imaging and therapeutic interventions that will be tailored for individuals based on the ability of the receptors to respond to specific probes as well as certain therapeutic interventions.

ITN: How has molecular imaging and nuclear medicine research led to improvements in the diagnosis and treatment of cancer, heart disease and brain disorders?
MS: It has the potential to affect a large variety of diseases, including cardiac disease, and various cancers. We have already seen it with monoclonal antibodies and there is the possibility of that certain brain disorders have the potential to be responsive, as well. It covers a host of different diseases.

ITN: Can you describe what the new program InfoSNM involves and what the objective is?
MS: We have developed a number of live, interactive lifelong learning programs and people can access the educational component and with that is a continuing medical education component that goes along with these. These are live, interactive programs. There is also training of clinicians and technologists with hybrid imaging, which is a key part of the molecular imaging process or where by you have a congruence of different technologies giving different synergistic kinds of information.

ITN: Exactly which hybrids are you referring to?
MS: These hybrids include PET/CT, SPECT/CT and also work being done on PET/MRI.
Simon Cherry, who gave the Henry Wagner lecture at last year’s SNM, showed that scientists have overcome the technical challenges of integrating PET and MRI imaging. There are models now that are being worked on now.
PET/MRI has the advantage s there is of less radiation and MR gives different kinds of information, such as MR spectroscopy’s the ability to overlap MR spectroscopy on a tumor and look at its therapeutic response. All of the different roles of MR versus CT can now be combined potentially with PET, as can CT.

ITN: What are some of the advancements you anticipate will develop in Nuclear Medicine over the next five years?
MS: Besides the translational development of new products and nanoparticle technology, I think that the biggest advancement will be bringing quantitative measurements to the bedside. If you look at cardiac imaging today, we are looking at relative blood flow. We steal blood from parts of the heart that have narrowing of blood vessels and look at compare it to other parts of the heart with normal blood flow. With pharmacological exercises we improve blood flow, we increase blood flow and we look at relative diminishment in blood flow. I think that we are soon going to have technologies, which have high enough contrast count rates and resolution such that we will have the same sensitivity for gamma camera imaging as we do with PET. This will allow us to quantitate absolute blood flow and the ml/min diminish for 100 grams of tissue. I think quantification is the next big breakthrough in imaging technology.

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...